M&A / Deals Cumberland to sell drug portfolio to Apotex for $100m Pharmaceutical Business ReviewUnder the agreement, Apotex will acquire Cumberland's branded medicines for cash, subject to approval by Cumberland's shareholders.M&A / DealsRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) Pharmaceutical Business Review Under the agreement, Apotex will acquire Cumberland’s branded medicines for cash, subject to approval by Cumberland’s shareholders. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA clears first genetic hearing loss gene therapyNext: Regeneron cuts White House pricing deal, offers new gene therapy for free Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
